Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Grading of Neurotoxicity in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Receiving Tisagenlecleucel Treatment in the JULIET Study

Richard T. Maziarz, MD, Stephen J. Schuster, MD, Vadim V. Romanov, MD MPhil, FFPM, Elisha S. Rusch, PhD, James Signorovitch, PhD, Solveig G. Ericson, MD PhD, David G. Maloney, MD PhD, Frederick L. Locke, MD

Blood (2018) 132 (Supplement 1): 4183.

https://doi.org/10.1182/blood-2018-99-118595

Published: 2018

Journal Articles

Consensus Grading of Cytokine Release Syndrome (CRS) in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Treated with Tisagenlecleucel on the JULIET Study

Stephen J. Schuster, MD, Richard T. Maziarz, MD, Solveig G. Ericson, MD PhD, Elisha S. Rusch, PhD, James Signorovitch, PhD, Vadim V. Romanov, MD MPhil, FFPM, Frederick L. Locke, MD, David G. Maloney, MD PhD

Blood (2018) 132 (Supplement 1): 4190.

https://doi.org/10.1182/blood-2018-99-113052

Published: 2018

Journal Articles

Refractory Cytokine Release Syndrome in Recipients of Chimeric Antigen Receptor (CAR) T Cells

Noelle V. Frey, MDMS, Bruce L. Levine, PhD, Simon F. Lacey, PhD BSc, Stephan A. Grupp, MD PhD, Shannon L Maude, MD PhD, Stephen J. Schuster, MD, Pamela Shaw, PhD, Wei-Ting Hwang, PhD, Mariusz A. Wasik, MD, Amrom Obstfeld, MD, Mimi Leung, MPH, Angela Shen, MD, Solveig G. Ericson, MD PhD, Jan J Melenhorst, PhD, Carl H. June, MD, David Porter, MD

Blood (2014) 124 (21): 2296.

https://doi.org/10.1182/blood.V124.21.2296.2296

Published: 2014

Journal Articles

Understanding United States (US) Treatment Practices for the Management of Chronic Myeloid Leukemia (CML) in Clinical Practice: A US Subgroup Analysis of the WORLD CML Registry.

Robert Hermann, MD FACP, Carole B. Miller, MD, Rosalind Catchatorian, MD, David S. Snyder, MD, Solveig G. Ericson, MD, PhD, Oleg Zernovak, MD, Matthews A Juma, Jorge E. Cortes, MD

Blood (2012) 120 (21): 2781.

https://doi.org/10.1182/blood.V120.21.2781.2781

Published: 2012

Journal Articles

Frequency of Molecular Monitoring Correlates with Long Term Outcomes in Chronic Phase Chronic Myelogenous Leukemia Treated with First-Line Imatinib: Results of a Community Survey

Stuart L. Goldberg, MD, Lei Chen, MD, PhD, Solveig G. Ericson, MD, PhD, Alexander R. Macalalad, MD, Annie Guerin, MSc, Nathan Liu, MPH, Michael Kaminsky, BSc, Eric Qiong Wu, PhD

Blood (2012) 120 (21): 1685.

https://doi.org/10.1182/blood.V120.21.1685.1685

Published: 2012

Journal Articles

Treatment Patterns Among Patients with Philadelphia Chromosome Positive Chronic Myeloid Leukemia (Ph+ CML) Treated with Imatinib in a Community Setting.

Kavita R Sail, MS, PhD, Lei Chen, MD, PhD, James Jackson, PharmD, MPH, Solveig G. Ericson, MD, PhD, Sally Haislip, RPh, Tamara Ibison, RN, James Gilmore, PharmD, Mansoor N Saleh, MD

Blood (2012) 120 (21): 3179.

https://doi.org/10.1182/blood.V120.21.3179.3179

Published: 2012

Journal Articles

Monitoring Patterns and Subsequent Outcomes Among Patients with Philadelphia Chromosome Positive Chronic Myeloid Leukemia (Ph+ CML) Treated with Imatinib in a Community Setting

James Jackson, PharmD, MPH, Lei Chen, MD, PhD, Kavita R Sail, MS, PhD, Solveig G. Ericson, MD, PhD, Sally Haislip, RPh, Joyce Sharpe, RN, James Gilmore, PharmD, Mansoor N Saleh, MD

Blood (2012) 120 (21): 2066.

https://doi.org/10.1182/blood.V120.21.2066.2066

Published: 2012

Journal Articles

Change in Chronic Low-Grade Nonhematologic Adverse Events (AEs) and Quality of Life (QoL) in Adult Patients (pts) with Philadelphia Chromosome–Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Switched From Imatinib (IM) to Nilotinib (NIL)

Jorge E. Cortes, MD, Jeffrey H. Lipton, MD, PhD, Carole B. Miller, MD, Sikander Ailawadhi, MD, Luke Akard, MD, Javier Pinilla-Ibarz, MD, PhD, Felice P. Lin, PharmD, Solveig G. Ericson, MD, PhD, Michael J. Mauro, MD

Blood (2012) 120 (21): 3782.

https://doi.org/10.1182/blood.V120.21.3782.3782

Published: 2012

Journal Articles

Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Final Results of the Z-MARK Study

Noopur Raje, Robert Vescio, MD, Charles W. Montgomery, MD, Joseph T Hadala, MS, Ghulam Warsi, PhD, Solveig G. Ericson, MD, PhD, Kenneth C. Anderson, MD

Blood (2012) 120 (21): 4077.

https://doi.org/10.1182/blood.V120.21.4077.4077

Published: 2012

Journal Articles

Effect of Switching to Nilotinib in Patients with Imatinib-Related Low-Grade Non-Hematologic Adverse Events

Jeffrey H. Lipton, MD, PhD, Michael J. Mauro, MD, Sikander Ailawadhi, MD, Carole B. Miller, MD, Lambert Busque, MD, Luke P. Akard, MD, Javier Pinilla-Ibarz, MD, PhD, Solveig G. Ericson, MD- PhD, Jinay Shah, MS, Jorge E. Cortes

Blood (2011) 118 (21): 4422.

https://doi.org/10.1182/blood.V118.21.4422.4422

Published: 2011

Journal Articles

Bone Marker Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Primary Analysis Results of the Z-MARK Study

Noopur Raje, MD, Robert Vescio, MD, Charles W. Montgomery, MD, Ramakrishnan Parameswaran, MD, Diep Tran, MS, Ghulam Warsi, PhD, Eliza Argonza-Aviles, RN, MSHS, Solveig G. Ericson, MD- PhD, Kenneth C. Anderson, MD

Blood (2011) 118 (21): 5122.

https://doi.org/10.1182/blood.V118.21.5122.5122

Published: 2011

Journal Articles

Effect of Nilotinib (NIL) on Molecular Response in Chronic Myelogenous Leukemia - Chronic Phase (CML-CP) Patients (pts) with a Suboptimal Molecular Response to Imatinib (IM)–ENABL Study Update

Sikander Ailawadhi, MD, Carole B. Miller, MD, Anand P. Jillella, MD, Nebu Koshy, MD, Brian Tudor, MD, Luke P. Akard, MD, Solveig G. Ericson, MD- PhD, Felice P. Lin, PharmD, Jerald P. Radich, MD, Daniel J. DeAngelo, MD, PhD

Blood (2011) 118 (21): 2771.

https://doi.org/10.1182/blood.V118.21.2771.2771

Published: 2011

Journal Articles

Comparison of Skeletal Complications and Treatment Patterns Associated with Early Versus Delayed Zoledronic Acid Therapy In Multiple Myeloma

Andrew Peng Yu, PhD, Arielle G Bensimon, BA, Maryna Marynchenko, MBA, Eric Qiong Wu, PhD, Madhav Namjoshi, PhD, Amy Guo, PhD, Solveig G Ericson, MD, PhD, Noopur Raje, MD

Blood (2010) 116 (21): 1956.

https://doi.org/10.1182/blood.V116.21.1956.1956

Published: 2010

Journal Articles

Bone Marker Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications In Patients with Multiple Myeloma: Interim Analysis Results of the Z-MARK Study

Blood (2010) 116 (21): 2971.

https://doi.org/10.1182/blood.V116.21.2971.2971

Published: 2010

NARROW

Grading of Neurotoxicity in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Receiving Tisagenlecleucel Treatment in the JULIET Study

Consensus Grading of Cytokine Release Syndrome (CRS) in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Treated with Tisagenlecleucel on the JULIET Study

Refractory Cytokine Release Syndrome in Recipients of Chimeric Antigen Receptor (CAR) T Cells

Understanding United States (US) Treatment Practices for the Management of Chronic Myeloid Leukemia (CML) in Clinical Practice: A US Subgroup Analysis of the WORLD CML Registry.

Frequency of Molecular Monitoring Correlates with Long Term Outcomes in Chronic Phase Chronic Myelogenous Leukemia Treated with First-Line Imatinib: Results of a Community Survey

Treatment Patterns Among Patients with Philadelphia Chromosome Positive Chronic Myeloid Leukemia (Ph+ CML) Treated with Imatinib in a Community Setting.

Monitoring Patterns and Subsequent Outcomes Among Patients with Philadelphia Chromosome Positive Chronic Myeloid Leukemia (Ph+ CML) Treated with Imatinib in a Community Setting

Change in Chronic Low-Grade Nonhematologic Adverse Events (AEs) and Quality of Life (QoL) in Adult Patients (pts) with Philadelphia Chromosome–Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Switched From Imatinib (IM) to Nilotinib (NIL)

Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Final Results of the Z-MARK Study

Effect of Switching to Nilotinib in Patients with Imatinib-Related Low-Grade Non-Hematologic Adverse Events

Bone Marker Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Primary Analysis Results of the Z-MARK Study

Effect of Nilotinib (NIL) on Molecular Response in Chronic Myelogenous Leukemia - Chronic Phase (CML-CP) Patients (pts) with a Suboptimal Molecular Response to Imatinib (IM)–ENABL Study Update

Comparison of Skeletal Complications and Treatment Patterns Associated with Early Versus Delayed Zoledronic Acid Therapy In Multiple Myeloma

Bone Marker Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications In Patients with Multiple Myeloma: Interim Analysis Results of the Z-MARK Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only